One of the underrated but true successes of precision medicine has been pharmacogenomics. Beginning in the ’90s with the approval of the drug Herceptin for HER2 positive breast cancer, tailoring drugs to genotype has been one of the less controversial areas of our field and will only continue to build on the early promise of sequencing the human genome.

Today we talk Michelle Whirl-Carrillo, Director of PharmGKB, a one-stop go-to for pharmacogenomics data that has been funded by the NIH since 2000.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe